Current status of D-penicillamine therapy in Japan.

A multicentric post-marketing surveillance study over 7 years including 5,124 patients is presented. According to clinical and laboratory data, the drug D-penicillamine was effective, with a tendency of loss of efficacy after therapy of 5 years or longer. Response was better in the early stage of the disease. Side effects were observed in 28.1% of the patients.